Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of oncology therapeutics designed to radically improve outcomes for patients with unmet needs in oncology. The company's therapeutics include a new class of oncology called Resistance Mechanism Inhibitors (RMIs), that feature multiple simultaneous mechanisms of action and synergy in combination with other treatments, including immunotherapies in a preclinical model, enabling oncologists to treat haematological cancers easily.
You’re viewing a free company profile from the PitchBook Platform. To explore OncoSynergy’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Early Stage VC (Series A1) | 02-Aug-2019 | $1.15M | 000.00 | 000.00 | Completed | Generating Revenue |
5. Seed Round | 14-May-2018 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
4. Accelerator/Incubator | 19-May-2017 | 000.00 | Completed | Generating Revenue | ||
3. Accelerator/Incubator | 000.00 | Completed | Generating Revenue | |||
2. Merger/Acquisition | 05-Apr-2016 | Cancelled | Generating Revenue | |||
1. Seed Round | 28-Jun-2015 | $10.2M | $10.2M | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|---|---|---|---|---|---|---|---|
Series A1 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Kesios | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 0000 | 000000 - 000 | 0000 |
00000000 | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
000 0000000000000 | Venture Capital-Backed | Chester, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
0000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
Connecticut Innovations | Venture Capital | Minority | 000 0000 | 000000 0 | ||
Korea Information & Communications Company | Corporation | Minority | 000 0000 | 000000 0 | ||
NLabs | Family Office | Minority | 000 0000 | 000000 0 | ||
JLABS | Accelerator/Incubator | 000 0000 | 000000 0 | |||
California Institute for Quantitative Biosciences | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |
Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
Allen Salmasi Ph.D | Self | Chairman | 000 0000 | |
Amanda Hayward Ph.D | Connecticut Innovations | Board Member | 000 0000 | |
Anne-Marie Carbonell | OncoSynergy | Co-Founder, Chief Medical Officer & Board Member | 000 0000 | |
Hen-Suh Park Ph.D | OncoSynergy | Board Member | 000 0000 | |
Robert Dunkle | OncoSynergy | Board Member | 000 0000 |